| Methods |
Minimum 1‐week washout; 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg on 2 separate visits at end of placebo run‐in, with difference between visits of 10 mm Hg or less; 8‐week double‐blind treatment |
| Participants |
Moexipril 7.5 mg: n=16(12 males,4 females); mean age=56(12) years; baseline sitting SBP=161(12) mm Hg, DBP=103(4) mm Hg, HR=76(8) bpm;
Moexipril 15 mg: n=18(16 males,2 females); mean age=58(9) years; baseline sitting SBP=157(13) mm Hg, DBP=104(4) mm Hg, HR=78(13) bpm;
Placebo: n=17(15 males,2 females); mean age=50(12) years; baseline sitting SBP=149(17) mm Hg, DBP=106(4) mm Hg, HR=77(8) bpm |
| Interventions |
Moexipril 7.5 mg once daily;
Moexipril 15 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in trough sitting HR |
| Notes |
BP change and SD of change reported, endpoint BP and SD not reported; change in BP data from Table II, p. 235; Jadad score=2; funding source= Schwarz Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
